Safety and efficacy of nazartinib (EGF816) in adults with EGFR-mutant non-small-cell lung carcinoma: a multicentre, open-label, phase 1 study-Reference-Cited by-同舟云学术

Safety and efficacy of nazartinib (EGF816) in adults with EGFR-mutant non-small-cell lung carcinoma: a multicentre, open-label, phase 1 study

Published:2020-06 Issue:6 Volume:8 Page:561-572
ISSN:2213-2600
Container-title:The Lancet Respiratory Medicine
language:en
Short-container-title:The Lancet Respiratory Medicine

Author:

Tan Daniel S-W,Leighl Natasha B,Riely Gregory J,Yang James C-H,Sequist Lecia V,Wolf Juergen,Seto Takashi,Felip Enriqueta,Aix Santiago P,Jonnaert Maud,Pan Chun,Tan Eugene Y,Ko Jinnie,Moody Susan E,Kim Dong-Wan

Funder

National Medical Research Council

“Non-Small Cell Lung Cancer: Targeting Cancer Stem Cell and Drug Resistance”

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine

Reference27 articles.

1. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs;Kris;JAMA,2014

2. Cancer genomics: diversity and disparity across ethnicity and geography;Tan;J Clin Oncol,2016

3. Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors;Gazdar;Oncogene,2009

4. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations;Sequist;J Clin Oncol,2013

5. Intrinsic resistance to EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer with activating EGFR mutations;Wang;OncoTargets Ther,2016

Cited by 48 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Capmatinib plus nazartinib in patients with EGFR-mutated non–small cell lung cancer;European Journal of Cancer;2024-09

2. Synthesis of Pharmacologically Potent Benzimidazole Analogs;Polycyclic Aromatic Compounds;2024-08-13

3. Capmatinib plus nivolumab in pretreated patients with EGFR wild-type advanced non–small cell lung cancer;Lung Cancer;2024-06

4. Benzimidazole-Based Derivatives as Apoptotic Antiproliferative Agents: Design, Synthesis, Docking, and Mechanistic Studies;Molecules;2024-01-16

5. ABCB1 overexpression through locus amplification represents an actionable target to combat paclitaxel resistance in pancreatic cancer cells;Journal of Experimental & Clinical Cancer Research;2024-01-02